Cargando…

Development of Pyrazolone and Isoxazol-5-one Cambinol Analogues as Sirtuin Inhibitors

[Image: see text] Sirtuins are a family of NAD(+)-dependent protein deacetylases that play critical roles in epigenetic regulation, stress responses, and cellular aging in eukaryotic cells. In an effort to identify small molecule inhibitors of sirtuins for potential use as chemotherapeutics as well...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahajan, Sumit S., Scian, Michele, Sripathy, Smitha, Posakony, Jeff, Lao, Uyen, Loe, Taylor K., Leko, Vid, Thalhofer, Angel, Schuler, Aaron D., Bedalov, Antonio, Simon, Julian A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4002067/
https://www.ncbi.nlm.nih.gov/pubmed/24697269
http://dx.doi.org/10.1021/jm4018064
_version_ 1782313780089192448
author Mahajan, Sumit S.
Scian, Michele
Sripathy, Smitha
Posakony, Jeff
Lao, Uyen
Loe, Taylor K.
Leko, Vid
Thalhofer, Angel
Schuler, Aaron D.
Bedalov, Antonio
Simon, Julian A.
author_facet Mahajan, Sumit S.
Scian, Michele
Sripathy, Smitha
Posakony, Jeff
Lao, Uyen
Loe, Taylor K.
Leko, Vid
Thalhofer, Angel
Schuler, Aaron D.
Bedalov, Antonio
Simon, Julian A.
author_sort Mahajan, Sumit S.
collection PubMed
description [Image: see text] Sirtuins are a family of NAD(+)-dependent protein deacetylases that play critical roles in epigenetic regulation, stress responses, and cellular aging in eukaryotic cells. In an effort to identify small molecule inhibitors of sirtuins for potential use as chemotherapeutics as well as tools to modulate sirtuin activity, we previously identified a nonselective sirtuin inhibitor called cambinol (IC(50) ≈ 50 μM for SIRT1 and SIRT2) with in vitro and in vivo antilymphoma activity. In the current study, we used saturation transfer difference (STD) NMR experiments with recombinant SIRT1 and 20 to map parts of the inhibitor that interacted with the protein. Our ongoing efforts to optimize cambinol analogues for potency and selectivity have resulted in the identification of isoform selective analogues: 17 with >7.8-fold selectivity for SIRT1, 24 with >15.4-fold selectivity for SIRT2, and 8 with 6.8- and 5.3-fold selectivity for SIRT3 versus SIRT1 and SIRT2, respectively. In vitro cytotoxicity studies with these compounds as well as EX527, a potent and selective SIRT1 inhibitor, suggest that antilymphoma activity of this compound class may be predominantly due to SIRT2 inhibition.
format Online
Article
Text
id pubmed-4002067
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-40020672015-04-03 Development of Pyrazolone and Isoxazol-5-one Cambinol Analogues as Sirtuin Inhibitors Mahajan, Sumit S. Scian, Michele Sripathy, Smitha Posakony, Jeff Lao, Uyen Loe, Taylor K. Leko, Vid Thalhofer, Angel Schuler, Aaron D. Bedalov, Antonio Simon, Julian A. J Med Chem [Image: see text] Sirtuins are a family of NAD(+)-dependent protein deacetylases that play critical roles in epigenetic regulation, stress responses, and cellular aging in eukaryotic cells. In an effort to identify small molecule inhibitors of sirtuins for potential use as chemotherapeutics as well as tools to modulate sirtuin activity, we previously identified a nonselective sirtuin inhibitor called cambinol (IC(50) ≈ 50 μM for SIRT1 and SIRT2) with in vitro and in vivo antilymphoma activity. In the current study, we used saturation transfer difference (STD) NMR experiments with recombinant SIRT1 and 20 to map parts of the inhibitor that interacted with the protein. Our ongoing efforts to optimize cambinol analogues for potency and selectivity have resulted in the identification of isoform selective analogues: 17 with >7.8-fold selectivity for SIRT1, 24 with >15.4-fold selectivity for SIRT2, and 8 with 6.8- and 5.3-fold selectivity for SIRT3 versus SIRT1 and SIRT2, respectively. In vitro cytotoxicity studies with these compounds as well as EX527, a potent and selective SIRT1 inhibitor, suggest that antilymphoma activity of this compound class may be predominantly due to SIRT2 inhibition. American Chemical Society 2014-04-03 2014-04-24 /pmc/articles/PMC4002067/ /pubmed/24697269 http://dx.doi.org/10.1021/jm4018064 Text en Copyright © 2014 American Chemical Society
spellingShingle Mahajan, Sumit S.
Scian, Michele
Sripathy, Smitha
Posakony, Jeff
Lao, Uyen
Loe, Taylor K.
Leko, Vid
Thalhofer, Angel
Schuler, Aaron D.
Bedalov, Antonio
Simon, Julian A.
Development of Pyrazolone and Isoxazol-5-one Cambinol Analogues as Sirtuin Inhibitors
title Development of Pyrazolone and Isoxazol-5-one Cambinol Analogues as Sirtuin Inhibitors
title_full Development of Pyrazolone and Isoxazol-5-one Cambinol Analogues as Sirtuin Inhibitors
title_fullStr Development of Pyrazolone and Isoxazol-5-one Cambinol Analogues as Sirtuin Inhibitors
title_full_unstemmed Development of Pyrazolone and Isoxazol-5-one Cambinol Analogues as Sirtuin Inhibitors
title_short Development of Pyrazolone and Isoxazol-5-one Cambinol Analogues as Sirtuin Inhibitors
title_sort development of pyrazolone and isoxazol-5-one cambinol analogues as sirtuin inhibitors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4002067/
https://www.ncbi.nlm.nih.gov/pubmed/24697269
http://dx.doi.org/10.1021/jm4018064
work_keys_str_mv AT mahajansumits developmentofpyrazoloneandisoxazol5onecambinolanaloguesassirtuininhibitors
AT scianmichele developmentofpyrazoloneandisoxazol5onecambinolanaloguesassirtuininhibitors
AT sripathysmitha developmentofpyrazoloneandisoxazol5onecambinolanaloguesassirtuininhibitors
AT posakonyjeff developmentofpyrazoloneandisoxazol5onecambinolanaloguesassirtuininhibitors
AT laouyen developmentofpyrazoloneandisoxazol5onecambinolanaloguesassirtuininhibitors
AT loetaylork developmentofpyrazoloneandisoxazol5onecambinolanaloguesassirtuininhibitors
AT lekovid developmentofpyrazoloneandisoxazol5onecambinolanaloguesassirtuininhibitors
AT thalhoferangel developmentofpyrazoloneandisoxazol5onecambinolanaloguesassirtuininhibitors
AT schuleraarond developmentofpyrazoloneandisoxazol5onecambinolanaloguesassirtuininhibitors
AT bedalovantonio developmentofpyrazoloneandisoxazol5onecambinolanaloguesassirtuininhibitors
AT simonjuliana developmentofpyrazoloneandisoxazol5onecambinolanaloguesassirtuininhibitors